CT Financial Advisors’s TherapeuticsMD TXMD Stock Holding History

CT Financial Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$7.92K	Buy	22 +10	+83%	+$3.1K	﹤0.01%	475
2016 Q4	$3.46K	Hold	12	–	–	﹤0.01%	529
2016 Q3	$4.09K	Hold	12	–	–	﹤0.01%	514
2016 Q2	$5.1K	Buy	12 +6	+100%	+$2.47K	﹤0.01%	502
2016 Q1	$1.92K	Buy	+6	New	+$2.05K	﹤0.01%	561

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

CT Financial Advisors's TXMD Position: Q1 2017 in Review

CT Financial Advisors increased its TherapeuticsMD (TXMD) stake by 83% in Q1 2017, buying an estimated $3.1K and bringing the position to 22 shares worth $7.92K. The position accounts for ﹤0.01% of the portfolio, ranked #475.

CT Financial Advisors first reported a position in TXMD in Q1 2016 and has held it in 5 quarters since. 138 funds tracked by Wall St. Rank hold TXMD as of Q1 2017.

CT Financial Advisors held 22 shares of TherapeuticsMD worth $7.92K as of Q1 2017.
CT Financial Advisors bought 10 TherapeuticsMD shares in Q1 2017, an estimated $3.1K.
TherapeuticsMD made up ﹤0.01% of CT Financial Advisors's portfolio in Q1 2017, its #475 holding.
CT Financial Advisors first reported a position in TherapeuticsMD in Q1 2016 and has held it in 5 quarters since.
138 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.